Sources and Guidelines Referenced

The clinical information in this guide is grounded in established vitreoretinal practice guidelines and peer-reviewed ophthalmic evidence, including: American Academy of Ophthalmology (AAO) Preferred Practice Pattern Guidelines for Retinal Detachment (2020), Diabetic Retinopathy (2020), and Idiopathic Macular Hole (2021); European Society of Retina Specialists (EURETINA) Guidelines for Management of Rhegmatogenous Retinal Detachment (2019); Royal College of Ophthalmologists (RCOphth) Vitreoretinal Surgery Focus Guides (2021); Microincision Vitrectomy Surgery Evaluation Studies (Fujii et al., 2002; Eckardt, 2005); Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S and W findings; and the Silicone Study Group Trial Reports (McCuen et al., 1992).

Vitrectomy: A Comprehensive Patient Guide

1. Definition and Medical Identity

Vitrectomy is a microsurgical ophthalmic operation involving the removal of the vitreous humour—the transparent gel-like fluid filling the rear chamber of the eye—to treat disorders of the posterior segment. Known formally as pars plana vitrectomy (PPV), this specialized surgical procedure belongs to the medical discipline of vitreoretinal surgery. Its core clinical objective is to relieve mechanical traction, eliminate visual line obstructions, and facilitate internal repairs to the neurosensory retina and underlying vascular structures.

The surgery is designated as 'pars plana' because surgical entry sites are placed precisely through the pars plana—a 4-millimetre-wide avascular zone located behind the iris and anterior to the peripheral functional retina. Accessing the posterior eye cavity through this specific anatomical window prevents damage to both the clear anterior cornea and the fragile light-detecting neural tissue of the retina. Depending on the instrument gauge size utilized, the procedure is classified as standard or microincision vitrectomy surgery (MIVS), utilizing 23-gauge (0.6 mm), 25-gauge (0.5 mm), or 27-gauge (0.4 mm) sutureless self-sealing trocars.

2. The Underlying Condition or Need

Vitrectomy addresses pathological disruptions in the posterior ocular cavity that obscure light transmission, distort visual image formation, or physically pull the retina away from its underlying blood supply. The fundamental biological problem stems from pathological changes within the vitreous gel matrix or diseased fibrovascular growth along the inner surface of the retina.

Under normal physiological conditions, the vitreous is optically clear and firmly attached to the internal limiting membrane of the retina. As the eye ages or under pathological influences such as uncontrolled diabetes mellitus, high axial myopia (nearsightedness), or eye trauma, the gel undergoes synchysis (liquefaction) and syneresis (shrinkage). This contraction exerts pull forces, known as vitreoretinal traction, on vulnerable areas of the retina. If left untreated, tractional vectors can create retinal tears leading to rhegmatogenous retinal detachment, incite severe internal bleeding termed vitreous haemorrhage, or physically pull open the macula—the central focus area of detailed vision—resulting in profound, irreversible loss of central visual acuity.

3. How the Treatment Works — Mechanism

Vitrectomy works by surgically uncoupling the mechanical and structural link between the vitreous gel matrix and the neurosensory retina, thereby permanently removing tension forces and visual axis opacities. The surgeon cuts and evacuates the gel while simultaneously replacing lost intraocular fluid volume with physiological liquid to maintain normal eye shape and pressure.

At the mechanical level, a high-speed pneumatic or electric vitreous cutter utilizes an internal reciprocating guillotine blade that oscillates at rates between 5,000 and 10,000 cuts per minute. This ultra-high cut rate shears the long-chain collagen polymers and hyaluronic acid molecules of the vitreous gel into minute fluid fragments, which are continuously aspirated through a vacuum port. Simultaneously, an intraocular infusion cannula pumps a balanced salt solution into the posterior segment at a controlled pressure, preventing surgical collapse of the globe (hypotony).

Once the gel is cleared, micro-instruments including micro-forceps, micro-scissors, and laser probes enter the open cavity. The surgeon uses micro-forceps to peel microscopic scar tissue (epiretinal membranes) from the macular surface with sub-millimetre precision. To seal retinal tears or halt abnormal blood vessel growth, an endolaser probe applies precise thermal coagulation spots around retinal defects, creating permanent chorioretinal scars that seal the neurosensory retina against the underlying pigmented epithelium layer.

4. Types and Variations

Vitrectomy protocols are categorized by instrument diameter (gauge size), surgical access approach, and the type of intraocular tamponade agent introduced at the conclusion of the procedure to stabilize the repaired retina.

Instrumentation gauge selection determines surgical invasiveness, recovery speed, and fluidic stability. Modern vitreoretinal surgery predominantly utilizes sutureless microincision vitrectomy surgery (MIVS) platforms. Additionally, surgery may be combined with anterior segment operations, such as phacoemulsification for cataract removal, termed a combined phaco-vitrectomy.

Vitrectomy Type / Gauge	Incision Diameter	Suture Requirement	Primary Clinical Indications	Clinical Trade-offs
20-Gauge (Legacy)	0.9 mm	Sutures mandatory (10-0 Vicryl)	Complex trauma, large intraocular foreign body extraction	Higher wound inflammation, longer operating time, suture-related discomfort.
23-Gauge MIVS	0.6 mm	Usually sutureless (occasional suture)	Dense vitreous haemorrhage, complex tractional retinal detachment	High instrument rigidity, excellent fluidics, slightly larger entry site than 25G.
25-Gauge MIVS	0.5 mm	Sutureless (self-sealing)	Rhegmatogenous retinal detachment, macular holes, epiretinal membranes	Optimal balance of instrument stiffness and rapid wound closure; fast recovery.
27-Gauge MIVS	0.4 mm	Sutureless (self-sealing)	Focal macular surgery, pediatric retina, delicate membrane peeling	Ultra-smooth wound healing, minimal tissue trauma; trade-off is flexible instruments and lower flow rates.

At the end of surgery, the surgeon selects an appropriate internal tamponade agent based on the condition being treated:

• Balanced Salt Solution (BSS): Short-acting fluid substitute used when simple clear vitreous removal or non-tractional bleeding is managed without active retinal tears.
• Air Tamponade: Absorbs rapidly within 3 to 7 days; suitable for simple superior retinal tears or uncomplicated macular procedures.
• Sulfur Hexafluoride (SF6) Gas: Intermediate-acting gas that expands roughly two-fold and remains in the eye for 2 to 3 weeks. Ideal for central macular holes.
• Perfluoropropane (C3F8) Gas: Long-acting gas that expands four-fold and persists for 6 to 8 weeks; used for complex, inferior, or recurrent retinal detachments.
• Silicone Oil: Non-absorbable liquid tamponade providing long-term structural support (months to years) for severe giant retinal tears, complex trauma, or severe proliferative vitreoretinopathy. Requires a second operation for subsequent removal.

5. Who the Treatment Is For — Indications

Vitrectomy is indicated for patients experiencing structural integrity loss, non-clearing opacities, or progressive mechanical damage within the posterior segment of the eye, as outlined by the American Academy of Ophthalmology (AAO) Preferred Practice Patterns.

Diagnostic workup involves complete ophthalmic evaluation including visual acuity testing, dilated funduscopy, optical coherence tomography (OCT), and ocular B-scan ultrasonography when media opacities block direct optical viewing. Specific clinical indications include:

• Rhegmatogenous Retinal Detachment (RRD): Full-thickness retinal break allowing subretinal fluid accumulation; surgery is indicated urgently to reattach the retina before permanent photoreceptor death occurs.
• Non-Clearing Vitreous Haemorrhage: Intraocular bleeding, secondary to diabetic retinopathy or retinal vein occlusion, that fails to reabsorb spontaneously after 1 to 3 months.
• Proliferative Diabetic Retinopathy (PDR): Tractional retinal detachment threatening or involving the macula, or severe fibrovascular proliferation unresponsive to intravitreal anti-VEGF therapy or panretinal photocoagulation (DRCR.net Protocol S, 2015).
• Idiopathic Macular Hole: Full-thickness defect in the fovea (stages 2, 3, and 4) causing central scotoma and visual distortion (metamorphopsia).
• Epiretinal Membrane (ERM): Premacular fibrocellular tissue contraction reducing central vision below 20/40 or causing severe visual distortion impairing daily activities.
• Vitreomacular Traction (VMT) Syndrome: Incomplete posterior vitreous detachment exerting focal mechanical tension on the central macula.
• Acute Endophthalmitis: Severe bacterial or fungal intraocular infection requiring therapeutic surgical debulking and direct intravitreal antibiotic instillation (Endophthalmitis Vitrectomy Study, 1995).
• Ocular Trauma: Penetrating injuries with retained intraocular foreign bodies, intraocular lens dislocation into the posterior cavity, or traumatic vitreous disruption.

6. Who the Treatment Is NOT For — Contraindications

Vitrectomy is contraindicated when underlying eye conditions make functional vision restoration biologically impossible, or when systemic health risks preclude safe administration of surgical anesthesia.

Absolute contraindications include cases of absolute eye disease where there is zero light perception (no light perception, NLP) due to total optic nerve atrophy or irreversible photoreceptor loss, as surgical intervention carries surgical risk without potential functional visual benefit. Additional contraindications include active, uncontrolled systemic sepsis, or severe terminal systemic illnesses where surgical stress presents an unacceptable mortality risk.

Relative contraindications requiring pre-operative stabilization or protocol modification include:

• Uncontrolled Systemic Hypertension: High systemic blood pressure significantly increases intraoperative risk of catastrophic suprachoroidal haemorrhage (massive bleeding under the choroid layer).
• Severe Uncontrolled Coagulopathy: Patients with severe bleeding disorders or unmanaged therapeutic anticoagulation; blood clotting markers must be optimized before elective vitreoretinal surgery.
• Inability to Maintain Post-Operative Positioning: Patients with severe cervical spine rigidity, advanced physical disability, or severe cognitive disorders who cannot maintain mandatory face-down prone positioning required for gas tamponade success. In such individuals, alternative non-expansile tamponades like silicone oil or non-positioning surgical techniques must be evaluated.
• Advanced Neovascular Glaucoma: Severe ocular ischemia with complete angle closure, where intraocular pressure cannot be medically controlled.

7. Alternatives and Clinical Comparison

Depending on the underlying posterior segment pathology, alternative medical or surgical strategies may be considered before proceeding to full pars plana vitrectomy.

For rhegmatogenous retinal detachment, scleral buckling—a procedure where a flexible silicone band or sponge is sewn onto the outer surface of the eye (sclera) to push the wall of the eye inward against the retinal tear—remains an established alternative or adjunct. For superior uncomplicated retinal tears, pneumatic retinopexy can be performed in an outpatient clinic setting. For diabetic vitreous hemorrhage, medical management using intravitreal anti-VEGF injections (e.g., ranibizumab, aflibercept) may stimulate blood reabsorption without open surgery.

Clinical Approach	Mechanism of Action	Invasiveness	Anesthetic Requirement	Primary Clinical Trade-offs
Pars Plana Vitrectomy (PPV)	Internal gel removal, direct membrane peeling, laser, gas/oil tamponade	Microsurgical intraocular intervention	Local retrobulbar block or general anesthesia	Highest visual clarity restoration; requires positioning; causes accelerated cataract in natural lenses.
Scleral Buckling	External indentation of sclera using silicone element to close retinal tears	Extraocular surgical intervention	Local retrobulbar block or general anesthesia	Preserves vitreous gel; no accelerated cataract formation; causes refractive shift (myopic shift) and extraocular muscle diplopia risk.
Pneumatic Retinopexy	In-clinic intraocular gas bubble injection combined with cryotherapy or laser	Minimally invasive office procedure	Topical or sub-tenon local anesthesia	Low invasiveness, low cost; limited to simple superior retinal breaks; lower primary success rate (approx 70–80%).
Intravitreal Anti-VEGF Therapy	Pharmacological inhibition of vascular endothelial growth factor to stop bleeding	In-clinic intravitreal injection	Topical local drop anesthesia	Non-surgical; highly effective for macular edema and proliferative disease; requires repeated monthly injections; fails to clear dense organized clot.

8. Pre-Treatment Phase

The pre-operative phase optimizes ocular visualization, confirms anatomical diagnoses, and manages systemic comorbidities to ensure intraoperative safety and maximal functional recovery.

Initial consultation includes testing of best-corrected visual acuity (BCVA), intraocular pressure (IOP) measurement via goldmann applanation tonometry, slit-lamp examination of the anterior segment, and dilated indirect ophthalmoscopy. Diagnostic imaging plays a critical role: optical coherence tomography (OCT) produces high-resolution cross-sectional microstructural images of retinal layers to quantify macular thickness, edema, and vitreomacular traction. If dense vitreous bleeding or cataract completely blocks optical access to the fundus, an ocular B-scan ultrasonography is performed to rule out underlying retinal detachment or intraocular mass.

Systemic pre-operative clearance includes evaluating blood pressure control and glycemic status. In diabetic patients, controlling blood glucose levels lowers post-operative infection risks and minimizes delayed wound healing. Patients using oral anticoagulants (such as warfarin or direct oral anticoagulants) are evaluated individually by the surgical team; while routine antiplatelet therapy (aspirin) is usually continued, stronger anticoagulants may require temporary dosage adjustment based on individualized bleeding versus thrombotic risk assessments (AAO PPP Retinal Detachment Guidelines, 2020).

Patient counseling focuses on set-up requirements for post-operative recovery. If an expandable gas tamponade is anticipated, patients receive instructions regarding post-operative face-down prone positioning and are informed about strict air travel restrictions while gas remains in the eye.

9. The Procedure — Step-by-Step Clinical Detail

Vitrectomy is performed in a sterile ophthalmic operating theatre under high-magnification surgical operating microscopes, typically operating as a day-surgery outpatient procedure lasting between 45 and 90 minutes.

Step 1: Surgical Preparation and Anesthesia

The patient is placed in a supine position. The periocular skin and ocular surface are disinfected with 5% povidone-iodine solution. Anesthesia is most commonly achieved via a retrobulbar or peribulbar block, where local anesthetic (such as a 50:50 mixture of 2% lidocaine and 0.5% bupivacaine) is injected into the retrobulbar space behind the globe to provide total ocular anesthesia and akinesia (paralysis of eye movements). Conscious intravenous sedation is maintained by an anesthetist. Alternatively, general anesthesia is utilized for anxious patients, pediatric populations, or complex prolonged trauma cases.

Step 2: Trocar Placement and Infusion Setup

The surgeon places three (or four) micro-incisional valve trocars through the pars plana region, positioned 3.5 millimetres (in pseudophakic eyes with artificial lenses) or 4.0 millimetres (in phakic eyes with natural lenses) posterior to the corneal limbus. The three entry sites accommodate: (1) an automated intraocular infusion line to continuously maintain fluid volume and intraocular pressure; (2) an endoilluminator fiber-optic light pipe to light the dark posterior cavity; and (3) an active surgical instrument port (for the vitreous cutter, micro-forceps, or laser probe).

Step 3: Core and Peripheral Vitrectomy

Under continuous microscope visualization assisted by wide-field non-contact viewing lenses, the surgeon introduces the vitreous cutter. Gel removal begins in the central vitreous cavity (core vitrectomy). The cutter is then advanced toward the peripheral retina to excise liquefied gel and tractional strands (peripheral vitrectomy). Indentation of the outer eye wall (scleral depression) by an assistant helps bring the far peripheral vitreous base into view for thorough cleaning.

Step 4: Micro-Membrane Peeling and Retinal Repair

If an epiretinal membrane or macular hole is present, microscopic forceps are used to perform internal limiting membrane (ILM) peeling. A biocompatible vital dye, such as Brilliant Blue G or Trypan Blue, is injected into the cavity to stain and delineate the microscopic membrane layer. The surgeon grasps the edge of the membrane and peels it smoothly off the macular surface in a circular motion (rhexis). If retinal tears are identified, fluid underneath the retina is aspirated (subretinal fluid drainage), and an endolaser probe applies precise heat spots around the tear boundaries to secure the retina.

Step 5: Intraocular Exchange and Tamponade Placement

Once retinal repair is complete, fluid inside the eye is exchanged for air (fluid-air exchange). Depending on the clinical goal, the air can then be exchanged for an expanding gas mixture (SF6 or C3F8) or medical-grade silicone oil. The gas or oil acts as an internal floating splint that holds the reattached retina firmly against the back wall of the eye and seals macular holes.

Step 6: Trocar Removal and Closure

The micro-trocars are removed from the pars plana ports. Modern 23-, 25-, and 27-gauge incisions feature angled, self-sealing sclera-corneal tunnel profiles that close spontaneously due to normal intraocular pressure. If an entry site shows minor fluid seepage, a single absorbable 10-0 Vicryl suture is placed to ensure absolute wound closure. Subconjunctival antibiotic and corticosteroid injections are administered, and the eye is covered with a sterile protective pad and rigid shield.

10. Immediate Post-Procedure Period

In the initial 24 to 48 hours following vitrectomy, patient care focuses on intraocular pressure regulation, pain management, and early postural compliance.

Patients are monitored in the recovery area for 1 to 2 hours post-surgery. Mild deep ocular aching or foreign-body sensation is normal and managed with oral paracetamol (acetaminophen); non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin are usually avoided unless approved by the surgeon due to minor bleeding risks. Nausea, which can occur secondary to retrobulbar block or elevated eye pressure, is managed with antiemetic medications.

The surgical eye pad and rigid shield remain untouched until the first post-operative day clinical review. Clinical discharge criteria mandate that the patient is systemically stable, demonstrates understanding of topical eye drop administration (typically broad-spectrum topical antibiotics and topical steroids such as 1% prednisolone acetate applied 4 times daily), and comprehends specific face-down prone positioning instructions.

If a gas bubble or silicone oil tamponade was placed to seal a central macular hole or superior retinal tear, strict adherence to face-down positioning must begin immediately. The gas bubble floats upward within the eye globe; holding the head face-down directs the buoyant force of the bubble straight against the macula at the center back of the eye, physically sealing the tissue defect.

11. Recovery — Short and Long Term

Full recovery following vitrectomy requires a step-by-step healing process lasting from 2 weeks to 6 months, dependent on the underlying condition and the tamponade agent used.

Short-Term Recovery (Weeks 1 to 2)

During the first week, visual acuity in a gas-filled eye is extremely limited; patients can typically perceive only hand motion or shadow movement because the light rays refract abnormally through the gas-fluid boundary. A distinct, dark horizontal line reflecting the upper edge of the gas bubble will be visible in the lower visual field. As the body absorbs the gas over time, this line drops lower until the bubble disappears completely.

Strict head positioning (prone or side-lying posture as instructed by the surgeon) is typically maintained for 3 to 14 days for 16 to 20 hours per day, utilizing specialized face-down recovery chairs or pillows. Daily activities involving heavy lifting (over 5–10 kilograms), strenuous exercise, bending below waist level, and rubbing the eye are strictly prohibited to prevent intraocular pressure spikes or incisional reopening.

Long-Term Recovery (Weeks 3 to 6 Months)

Short-acting SF6 gas reabsorbs completely in 2 to 3 weeks, while long-acting C3F8 gas requires 6 to 8 weeks for total reabsorption. Natural aqueous humour produced continuously by the eye replaces the gas volume automatically. Once the gas clears from the central visual axis, functional visual acuity progressively improves over several months.

Final visual recovery depends heavily on the pre-operative health of the macula and optic nerve. In cases where the central macula was detached prior to surgery (macula-off retinal detachment), maximum visual recovery may take 6 to 12 months to stabilize as photoreceptor microstructures gradually reorganize (EURETINA Guidelines, 2019). Routine eye drop medications are tapered slowly over 4 to 6 weeks. New spectacle prescriptions are deferred until at least 8 to 12 weeks post-operatively to ensure corneal curvature and refractive stability.

12. Risks, Side Effects, and Complications

While modern microincision vitrectomy is a highly refined surgical procedure, intraoperative and post-operative complications can occur. Complications are stratified by frequency and severity in the risk severity matrix below.

Frequency / Severity	Complication Name	Clinical Mechanism and Description	Clinical Management Strategy
Very Common / Mild to Moderate	Accelerated Cataract Formation	Nuclear sclerotic yellowing and opacification of natural lens in phakic eyes, triggered by intraocular hyperoxia and fluid changes during vitrectomy (occurs in up to 80% within 2 years).	Elective cataract extraction with intraocular lens implantation once eye is fully healed.
Common / Mild	Transient Elevated Intraocular Pressure	Post-operative ocular hypertension secondary to gas bubble expansion, inflammatory steroid response, or trabecular meshwork clogging.	Topical aqueous suppressant eye drops (e.g., timolol, dorzolamide); oral acetazolamide if severe.
Uncommon / Moderate	Recurrent Vitreous Haemorrhage	Post-operative re-bleeding from residual vascular membranes or sclerotomy entry sites.	Head elevation, activity restriction, observation; repeat vitrectomy if non-clearing after several weeks.
Uncommon / Moderate to Severe	Iatrogenic Retinal Tears or Redetachment	New retinal break created during peripheral vitreous manipulation or recurrent proliferative vitreoretinopathy (PVR) scar tissue (occurs in 5–10% of detachment cases).	Secondary vitrectomy with fluid-gas exchange, endolaser, or silicone oil tamponade.
Rare / Severe	Infectious Endophthalmitis	Severe intraocular bacterial infection introduced through surgical entry ports (incidence approx. 0.03–0.05%).	Emergency intravitreal antibiotic injections (vancomycin + ceftazidime) and repeat vitrectomy debulking.
Very Rare / Severe	Suprachoroidal Haemorrhage	Massive bleeding into the potential space between the choroid and sclera due to rapid intraocular pressure drops during surgery.	Immediate surgical port closure, systemic pressure control, delayed surgical drainage after clot liquefaction.

Critical Warning Signs Requiring Urgent Medical Evaluation

Patients must seek immediate emergency vitreoretinal evaluation if they experience any of the following warning signs during recovery:

• Sudden, severe, or escalating eye pain unresponsive to prescribed analgesics.
• Sudden, severe drop in visual acuity or total loss of light perception.
• Rapidly increasing redness, eyelid swelling, or purulent (pus-like) eye discharge.
• Appearance of new bright light flashes (photopsia) or sudden shower of dark spots in the non-gas visual field.
• A noticeable dark shadow or curtain progressing across any part of the remaining visual field.

13. Lifestyle and Behavioural Considerations

Patient adherence to post-operative instructions plays a pivotal role in determining the structural success of vitrectomy repairs.

Strict Postural Compliance (Prone Positioning)

When gas or silicone oil tamponade is used, maintaining correct head positioning is vital. Patients must keep their head face-down (parallel to the floor) so that the buoyancy of the light gas bubble pushes continuously against the macular hole or retinal break located at the posterior pole of the eye. Specialized recovery equipment, including face-down massage-style chairs, head-support mirrors, and sleeping cushions, can significantly improve physical comfort and compliance during the mandatory 3 to 14 day positioning window.

Critical Air Travel and Altitude Restriction

Strict Medical Warning: Any patient with an expansile gas bubble (SF6 or C3F8) inside their eye is strictly prohibited from flying in an aircraft or traveling to high altitudes (e.g., mountain driving above 1,000 meters). As ambient atmospheric pressure decreases at high altitudes, the gas bubble inside the eye expands rapidly according to Boyle's Law. Uncontrolled intraocular gas expansion causes catastrophic elevation of intraocular pressure, leading to retinal artery occlusion and permanent, irreversible blindness within hours. Flying is strictly forbidden until an eye care specialist confirms complete absorption of the gas bubble.

Hygiene and Physical Restrictions

To reduce bacterial endophthalmitis risks, water must not enter the operated eye for 2 weeks following surgery; showering below the neck is permitted, but hair washing should be done leaning backward with the eye shielded. Eye makeup, contact lenses, swimming pools, hot tubs, and dusty environments must be completely avoided for at least 4 weeks. Light walking is encouraged, but strenuous cardiovascular exercise, weight training, and contact sports are restricted for 4 to 6 weeks.

14. How Outcomes Are Measured

Vitreoretinal specialists evaluate surgical success through anatomical endpoints (structural healing) and functional endpoints (visual acuity improvement).

Anatomical Endpoints

The primary anatomical objective in retinal detachment surgery is complete 360-degree reattachment of the neurosensory retina onto the underlying retinal pigment epithelium, with clear structural resolution of subretinal fluid. In macular hole surgery, anatomical success is defined as complete 360-degree bridge closure of the neural macular defect, confirmed via cross-sectional optical coherence tomography (OCT) imaging. Large prospective studies demonstrate primary anatomical closure rates exceeding 90% to 95% for idiopathic macular holes under 400 microns (Jackson et al., 2013).

Functional Endpoints

Functional success is assessed by measuring changes in best-corrected visual acuity (BCVA) using standard Early Treatment Diabetic Retinopathy Study (ETDRS) vision charts. Additional functional markers include reduction in visual distortion (metamorphopsia) measured via Amsler grid charts and recovery of central contrast sensitivity. Visual improvement occurs gradually over 3 to 12 months as cellular photoreceptors recover, provided the macula remained attached prior to intervention or was rapidly reattached within acute treatment windows.

Indications for Repeat Procedure

A second surgical intervention may be required in cases of: (1) primary retinal redetachment due to advanced proliferative vitreoretinopathy (PVR); (2) unclosed persistent macular holes; (3) recurrent vitreous hemorrhage; or (4) elective scheduled removal of intraocular silicone oil tamponade (typically performed 3 to 6 months post-operatively once retinal stability is established).

Closure rates and anatomical metrics vary by clinical indication, baseline retinal structural integrity, and timeline to intervention. Maximum visual gains generally stabilize between 6 and 12 months post-procedure.

15. Recent Advances and Current Standard of Care

Over the past two decades, vitreoretinal surgery has evolved through engineering advances in micro-instrumentation, high-speed fluidics, intraoperative imaging, and surgical visualization systems.

The standard of care has transitioned from legacy 20-gauge sutured systems to sutureless microincision vitrectomy surgery (MIVS) using 23-, 25-, and 27-gauge entry platforms (Fujii et al., 2002; Eckardt, 2005). Modern MIVS features ultra-high-speed vitrectomy cutters capable of up to 20,000 cuts per minute using dual-pneumatic drive technology. High cut rates reduce vitreoretinal traction during vitreous gel excision, allowing safer proximity to delicate retinal structures and significantly decreasing iatrogenic retinal tear rates.

Another major technological evolution is the integration of intraoperative optical coherence tomography (iOCT) directly into the surgical operating microscope. Intraoperative OCT provides the surgeon with real-time, cross-sectional microscopic visualization of macular tissue layers during active membrane peeling, confirming complete removal of tractional scar tissue and verifying subretinal fluid clearance instantly during surgery.

Furthermore, 3D heads-up digital visualization systems have replaced traditional direct microscope eyepieces in many centers. Surgeons view high-definition, digitally enhanced 3D screens wearing polarized glasses, which improves depth perception, lowers required intraocular light intensity (reducing retinal phototoxicity risks), and enhances surgical ergonomic precision during long, complex retinal reconstructions.

16. Common Myths and Misconceptions

Myth: The eye is completely removed from the socket during vitrectomy surgery.
Reality: The eye globe is never removed from the eye socket during vitrectomy or any modern ophthalmic procedure. All microsurgical maneuvers are executed strictly inside the eye using microscopic instruments inserted through tiny 0.5 mm entry ports placed in the white part of the eye (sclera).

Myth: The removed vitreous gel will never be replaced, leaving an empty space inside the eye.
Reality: The body naturally produces aqueous humour—a clear, watery fluid—which continually flows into and fills the posterior cavity, replacing the removed vitreous gel. The aqueous fluid maintains intraocular pressure and optical clarity without any structural or functional deficiency.

Myth: Cataract surgery cannot be performed if a patient has previously undergone a vitrectomy.
Reality: Cataract surgery can be performed safely after vitrectomy. In fact, because vitrectomy accelerates natural cataract progression in phakic patients, cataract extraction with artificial intraocular lens (IOL) implantation is very common and routinely performed after vitreoretinal healing.

Myth: Laser treatment or eye drops can cure full-thickness macular holes and detached retinas without surgery.
Reality: Full-thickness macular holes and rhegmatogenous retinal detachments are structural physical defects that require mechanical repair. Eye drops and non-invasive medications cannot pull a detached retina back into position or close a mechanical macular hole; vitrectomy or extraocular surgery is medically necessary.

Myth: You can fly home immediately after vitrectomy surgery if you feel fine.
Reality: Flying with an intraocular gas bubble (SF6 or C3F8) is extremely dangerous regardless of how well the patient feels. Atmospheric pressure drops in an airplane cabin cause the gas bubble to expand rapidly, causing severe intraocular hypertension and potential permanent total blindness within hours. Flying is strictly contraindicated until gas reabsorption is complete.

Myth: Face-down positioning is required for every patient who undergoes a vitrectomy.
Reality: Face-down prone positioning is only required when an intraocular gas or silicone oil tamponade is utilized to repair specific macular defects or superior retinal tears. If the surgery is performed purely with liquid (balanced salt solution) for clear vitreous hemorrhage removal, no face-down positioning is needed.

17. Frequently Asked Questions

What is the difference between vitreous gel and aqueous humour?

Vitreous gel is a thick, jelly-like matrix of collagen and hyaluronic acid filling the large rear cavity of the eye from birth. Aqueous humour is a watery, fluid continuously produced in the front chamber. When vitreous gel is surgically removed during vitrectomy, the eye replaces the cavity volume naturally with aqueous fluid, which maintains normal intraocular shape, pressure, and optical transparency.

Is vitrectomy surgery painful?

The procedure itself is pain-free because the eye is thoroughly numbed using local retrobulbar anesthesia block combined with monitored intravenous sedation or general anesthesia. Following surgery, patients may experience mild aching, a scratchy foreign-body sensation, or eyelid tenderness for several days, which is managed effectively with standard non-prescription analgesics such as paracetamol.

How long does a vitrectomy procedure take to perform?

An uncomplicated vitrectomy for epiretinal membrane removal or simple vitreous hemorrhage typically takes 30 to 45 minutes. More complex procedures, such as repairing advanced tractional diabetic retinal detachment, severe trauma, or proliferative vitreoretinopathy, can require 60 to 90 minutes or longer depending on surgical complexity.

When can I return to work after vitrectomy?

Return-to-work timelines depend on occupational physical demands and whether intraocular gas was used. Patients with sedentary desk jobs not requiring face-down positioning may return within 1 to 2 weeks. Individuals performing heavy physical labor, working in dusty environments, or requiring high-level visual acuity may require 4 to 6 weeks off work before full clearance.

Why is face-down positioning necessary after macular hole surgery?

In macular hole surgery, an intraocular gas bubble is placed inside the eye cavity. Because gas floats upward, holding the head face-down directs the floating gas bubble against the macula at the back of the eye. The physical pressure of the bubble seals the hole shut, keeping fluid out and allowing delicate neural macular edges to fuse and heal together.

How long will the gas bubble stay in my eye?

The duration depends on the specific gas mixture utilized by the surgeon. Air lasts 3 to 7 days; Sulfur Hexafluoride (SF6) gas lasts approximately 2 to 3 weeks; and Perfluoropropane (C3F8) gas remains in the eye for 6 to 8 weeks. The body gradually absorbs the gas, replacing it naturally with clear aqueous fluid.

Can I drive after having a vitrectomy?

You cannot drive immediately after surgery or while a gas bubble remains in your central visual field. The gas bubble alters light refraction severely, reducing depth perception and visual acuity. Driving may resume only when the gas bubble has fully absorbed, visual acuity meets legal driving standards, and your vitreoretinal specialist provides formal clearance.

Will I get a cataract after vitrectomy surgery?

If you have not previously undergone cataract surgery, there is a high probability (up to 80% within 2 years) of developing an accelerated nuclear sclerotic cataract in the surgical eye. Increased intraocular oxygen tension after vitreous removal accelerates lens clouding. The resulting cataract is safely treated with standard cataract surgery when visual changes occur.

What happens if I accidentally look up or stop face-down positioning too early?

Briefly lifting your head to eat or take eye drops will not instantly destroy the surgical repair. However, persistent failure to maintain prescribed face-down posture reduces contact between the gas bubble and the macular hole or retinal tear, significantly lowering the chance of successful anatomical closure and increasing the risk of surgical failure.

Is silicone oil better than gas tamponade?

Neither is inherently better; each has distinct clinical indications. Gas reabsorbs naturally without needing a second surgery, making it the preferred choice for most macular holes and routine retinal detachments. Silicone oil does not reabsorb and provides stable, long-term support for severe complex detachments or patients unable to maintain face-down posture, but it requires a secondary procedure to remove the oil months later.

When can I resume exercise and sports after surgery?

Light walking may be resumed within a few days after surgery. Strenuous activities, including running, weightlifting, swimming, and high-impact sports, must be avoided for at least 4 to 6 weeks. Sweating, straining, and submersion in water increase intraocular pressure and elevate risk of infection or wound disruption.

How soon will my vision improve after vitrectomy?

Visual recovery depends on the underlying eye condition and tamponade agent. In fluid-filled eyes, visual clearing begins within days. In gas-filled eyes, vision remains severely blurred until the gas bubble shrinks below the central line of sight (typically 2 to 6 weeks). Final visual acuity refines slowly over 3 to 12 months as retinal cells recover.